Amyloidosis-inhibiting polypeptides and their use

1. An isolated polypeptide, comprising 12-23 contiguous amino acids according to the general formula X1-X2-X3-X4-X5 (SEQ ID NO: 1), wherein

X1 is 0-7 contiguous amino acid residues that do not alternate between L and D residues;

X2 is 5-9 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 3-5 contiguous amino acid residues that do not alternate between L and D residues and do not abut residues with an alternative chirality;

X4 is 4-12 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is 0-4 contiguous amino acid residues that do not alternate between L and D residues;

wherein the isolated polypeptide is not: RGE(m)N(1)S(w)MNEYSGW(t)M(n)L(k)MGR (SEQ ID NO: 2).

2. The isolated polypeptide of claim 1 , wherein X1 is 0-2 contiguous amino acid residues that do not alternate between L and D residues.

3. The isolated polypeptide of claim 1 , wherein X2 is 6-8 contiguous amino acid residues alternating between D amino acids and L amino acids.

4. The isolated polypeptide of claim 1 , wherein X4 is 6-12 contiguous amino acid residues alternating between D amino acids and L amino acids.

5. The isolated polypeptide of claim 1 , wherein X5 is 0-3 contiguous amino acid residues that do not alternate between L and D residues.

6. The isolated polypeptide of claim 1 , wherein at least one of the following is true:

(a) X1 is 0 or 1 amino acid;

(b) X2 is 5, 6, 8, or 9 contiguous amino acid residues alternating between D amino acids and L amino acids;

(c) X4 is 6, 8, 9, 10, 11, or 12 contiguous amino acid residues alternating between D amino acids and L amino acids; or

(d) X5 is 0, 1, 3, or 4 contiguous amino acid residues that do not alternate between L and D residues.

7. The isolated polypeptide of claim 1 , wherein

X1 is absent;

X2 is 5-7 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 3-5 contiguous amino acid residues that do not alternate between L and D residues and do not abut residues with an alternative chirality;

X4 is 6-11 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is 0 or 1 amino acid residue.

8. The isolated polypeptide of claim 1 , wherein

X1 is absent;

X2 is 7 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 3 contiguous amino acid residues that do not alternate between L and D residues;

X4 is 9 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is absent.

9. The isolated polypeptide of claim 1 , wherein

X1 is absent;

X2 is 8 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 3 contiguous amino acid residues that do not alternate between L and D residues;

X4 is 10 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is absent.

10. The isolated polypeptide of claim 1 , wherein

X1 is 2 contiguous amino acid residues that do not alternate between L amino acids and D amino acids;

X2 is 7 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 3 contiguous amino acid residues that do not alternate between L and D residues;

X4 is 9 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is 2 contiguous amino acid residues that do not alternate between L amino acids and D amino acids.

11. The isolated polypeptide of claim 1 , wherein

X1 is absent;

X2 X7 is 7 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 4 contiguous amino acid residues that do not alternate between L and D residues;

X4 is 8 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is absent.

12. The isolated polypeptide of claim 1 , wherein X2 and X4 are the same length.

13. The isolated polypeptide of claim 12 , wherein

X1 is absent;

X2 is 7 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 5 contiguous amino acid residues that do not alternate between L and D residues;

X4 is 7 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is absent.

14. The isolated polypeptide of claim 1 , wherein

X1 is absent;

X2 is 6 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 3 contiguous amino acid residues that do not alternate between L and D residues and do not abut residues with an alternative chirality;

X4 is 11 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is 1 amino acid residue.

15. The isolated polypeptide of claim 1 , wherein

X1 is absent;

X2 is 6 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 3 contiguous amino acid residues that do not alternate between L and D residues;

X4 is 10 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is 1 amino acid residue.

16. The isolated polypeptide of claim 1 , wherein

X1 is absent;

X2 is 8 contiguous amino acid residues alternating between D amino acids and L amino acids;

X3 is 3 contiguous amino acid residues that do not alternate between L and D residues;

X4 is 12 contiguous amino acid residues alternating between D amino acids and L amino acids; and

X5 is absent.

17. The isolated polypeptide of claim 1 according to the general formula

R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23 (SEQ ID NO: 119), wherein at least residues R1-R14 are present in the isolated polypeptide, and wherein

R1 is selected from the group consisting of S, (q), (l), (w), (e), and (k), or their reverse chiral counterparts;

R2 is selected from the group consisting of (l), Q, W, E, (d), and (n), or their reverse chiral counterparts;

R3 is selected from the group consisting of T, (k), (l), (q), and S, or their reverse chiral counterparts;

R4 is selected from the group consisting of (l), S, Q, (w), (n), and F, or their reverse chiral counterparts;

R5 is selected from the group consisting of D, (w), (l), and T, or their reverse chiral counterparts;

R6 is selected from the group consisting of (p), T, S, N, and W, or their reverse chiral counterparts;

R7 is selected from the group consisting of N, (w), and A, or their reverse chiral counterparts;

R8 is selected from the group consisting of R, A, T, and E, or their reverse chiral counterparts;

R9 is selected from the group consisting of (l), A, N, and Y, or their reverse chiral counterparts;

R10 is selected from the group consisting of T, A, S, and Y, or their reverse chiral counterparts;

R11 is selected from the group consisting of (l), (a), P, R, and W, or their reverse chiral counterparts;

R12 is selected from the group consisting of K, W, A, and (t), or their reverse chiral counterparts;

R13 is selected from the group consisting of (p), (t), (a), and M, or their reverse chiral counterparts;

R14 is selected from the group consisting of P, M, W, (q), E, and C, or their reverse chiral counterparts;

R15 is selected from the group consisting of (q), (t), and L, or their reverse chiral counterparts, or is absent;

R16 is selected from the group consisting of L, W, Q, P, (k), and C, or their reverse chiral counterparts, or is absent;

R17 is selected from the group consisting of (k), (w), (l), (q), (p), and E, or their reverse chiral counterparts, or is absent;

R18 is selected from the group consisting of E, D, L, and P, or their reverse chiral counterparts, or is absent;

R19 is selected from the group consisting of (p), (k), and N, or their reverse chiral counterparts, or is absent;

R20 is selected from the group consisting of N, Q, and K, or their reverse chiral counterparts, or is absent;

R21 is selected from the group consisting of K, R, and (q), or their reverse chiral counterparts, or is absent;

R22 is P, or its reverse chiral counterpart, or is absent; and

R23 is (p), or its reverse chiral counterpart, or is absent.

18. An isolated polypeptide, comprising at least 14 contiguous amino acids according to the general formula

R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23 (SEQ ID NO: 119), wherein at least residues R1-R14 are present in the isolated polypeptide, and wherein

R1 is selected from the group consisting of S, (q), (l), (w), (e), Q, and (k);

R2 is selected from the group consisting of (l), Q, W, L, E, (d), and (n);

R3 is selected from the group consisting of T, (k), (l), (q), and S;

R4 is selected from the group consisting of (l), S, Q, (w), (n), and F;

R5 is selected from the group consisting of D, (w), (l), and T;

R6 is selected from the group consisting of (p), T, S, N, and W;

R7 is selected from the group consisting of N, (w), and A;

R8 is selected from the group consisting of R, A, T, and E;

R9 is selected from the group consisting of (l), L, A, N, and Y;

R10 is selected from the group consisting of T, (t), A, (a), S, and Y;

R11 is selected from the group consisting of (l), L, (a), P, A, R, and W;

R12 is selected from the group consisting of K, (k), W, A, and (t);

R13 is selected from the group consisting of (p), (t), (a), and M;

R14 is selected from the group consisting of P, M, W, (q), E, and C;

R15 is selected from the group consisting of (q), (t), and L, or is absent;

R16 is selected from the group consisting of L, W, Q, P, (k), and C, or is absent;

R17 is selected from the group consisting of (k), (w), (l), (q), (p), P, and E, or is absent;

R18 is selected from the group consisting of E, D, L, (p), and P, or is absent;

R19 is selected from the group consisting of (p), (k), and N, or is absent;

R20 is selected from the group consisting of N, Q, and K, or is absent;

R21 is selected from the group consisting of K, R, and (q), or is absent;

R22 is P, or is absent; and

R23 is (p), or is absent.

19. A pharmaceutical composition, comprising:

(a) the isolated polypeptide of claim 1 ; and

(b) a pharmaceutically acceptable carrier.

20. A method for treating an amyloid disease, comprising administering to a subject with an amyloid disease an amount of the isolated polypeptide of claim 1 effective to treat the amyloid disease.

21. A method for diagnosing or prognosing an amyloid disease, comprising

(a) contacting a tissue sample from a subject at risk of having an amyloid disease with the isolated polypeptide of claim 1 , under conditions suitable for binding of the isolated polypeptide with an amyloid intermediate, if present in the tissue sample, to produce a binding complex;

(b) detecting binding complexes in the tissue sample; and

(c) diagnosing or prognosing an amyloid disease based on the detecting.